Zum Inhalt springen

Boehringer's Survodutide Did Not Raise Heart Risk in a 5,530-Person Phase 3 Safety Trial, as Boehringer Moves Toward Obesity Filings

12.11.2026 · 5 Min.

Shownotes

Boehringer Ingelheim's investigational weekly injection survodutide, a glucagon/GLP-1 dual agonist, did not increase the risk of major heart and blood-vessel events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial, presented at the American Heart Association's Scientific Sessions 2026 and published in The Lancet on November 9, 2026. The cardiovascular safety trial enrolled 5,530 adults with overweight or obesity and heart disease, chronic kidney disease, or at least two weight-related risk factors. The main combined endpoint (cardiovascular death, non-fatal heart attack, non-fatal stroke, coronary revascularization or heart failure event) occurred in 3.7% of people on survodutide and 4.1% on placebo (hazard ratio 0.89, 95% CI 0.67 to 1.18), meeting the goal of showing no increase in risk; the trial was not designed to show a heart benefit. Under the supplementary estimand at 72 weeks, weight fell by up to 13.7% versus 2.0% with placebo, systolic blood pressure by up to 6.68 versus 1.76 mmHg, and waist size by up to 11.96 versus 2.74 cm. Nausea and vomiting were far more common on survodutide, and 19.3% and 20.8% of people in the two survodutide arms stopped treatment because of gastrointestinal side effects, versus 1.9% on placebo; serious adverse events were similar across groups. Survodutide is not approved anywhere. Boehringer, which funded the trial, says it is moving toward regulatory submissions in obesity and told Fierce Biotech it aims to file for weight loss in the next year.

Sources

  • Boehringer Ingelheim press release (Nov 9, 2026), survodutide SYNCHRONIZE-CVOT results: globenewswire.com
  • The Lancet (Nov 9, 2026), Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT), abstract on PubMed: pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov, NCT06077864 (SYNCHRONIZE-CVOT): clinicaltrials.gov
  • Fierce Biotech (Nov 9, 2026), AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test: fiercebiotech.com
  • AJMC (Nov 9, 2026), Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT: ajmc.com

Cover: original code-generated illustration (no photo).

This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.

Visit glp1newspaper.com for today's stories and free email alerts.

Alle Folgen von GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Einstellungen

Darstellung

Sprache

Bestimmt, welche Sender dir auf der Startseite zuerst gezeigt werden.

Verlauf

Zuletzt gehörte Sender und Folgen und deine letzten Suchen liegen nur in diesem Browser.

Hinweise

Ein kurzer Hinweis, wenn ein Podcast, dem du folgst, eine neue Folge hat. Einzelne Podcasts stellst du über die Glocke auf ihrer Seite ab.

Konto

Favoriten speichern – in der App und auf der Website.

Tastenkürzel

/
Suche öffnen
Leertaste
Abspielen oder anhalten
← →
Im Player: 15 s zurück, 30 s vor (Folgen) · im Regal: nächste Kachel
↑ ↓
Im Regal: Ziel innerhalb der Kachel
Pos1 / Ende
Im Regal: erste bzw. letzte Kachel
Esc
Fenster oder Menü schließen
?
Diese Übersicht
Läuft gerade

Zur Senderseite

Als Nächstes

    Folgen mit „Als Nächstes“ vormerken – sie laufen nach der aktuellen Folge.